Development of Nucleolin targeted Anticancer Compounds

核素靶向抗癌化合物的开发

基本信息

  • 批准号:
    7356391
  • 负责人:
  • 金额:
    $ 24.77万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-04-01 至 2010-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): GRO26B and GRO29A are G-quartet forming aptamer oligonucleotides that have potent antiproliferative activity against cancer cells in vitro and in vivo. GRO26B has already entered Phase I clinical trials. They are active against a diverse range of tumor types (including lung, prostate, breast, and colon cancers) and are highly selective for malignant cells. The molecular target for these aptamers has been identified as nucleolin, a multifunctional phosphoprotein that is highly expressed in the nucleoli and plasma membrane of cancer cells. It is already well established that high levels of nucleolin expression predict rapid tumor growth rate and poor prognosis in many tumor types. Nucleolin is on the surface of tumor cells and not on the surface of normal cells and we have shown that molecules selectively targeting it enter tumor cells preferentially over normal cells. Therefore nucleolin is a cancer selective target with targeted molecules potentially having lower side effects and toxicity by not entering normal cells. We are undertaking an interdisciplinary approach to the discovery of new small molecules targeting nucleolin. Preliminary data indicate that molecules targeting nucleolin (for example, GRO26B and small molecules that we have already identified using our approach) can also exhibit growth inhibitory activity against cancer cells while not effecting normal cells. We propose that in understanding how GROs and small molecules bind to nucleolin, we can use structure-based drug design to generate new small molecule that have increased efficacy over oligonucleotide-based therapy. Specifically, we need to understand the properties and structures of the GROs and how they are related. Using that information we can examine the complexes with nucleolin to identify specific interactions that are favorable. We will target these regions to screen for new compounds that will be subsequently tested for anticancer effects. The significance of this research is that we could establish a new class of low toxicity small molecule anticancer agents targeted to nucleolin.
描述(由申请人提供):GRO26B和GRO29A是g -四重奏形成的适体寡核苷酸,在体外和体内对癌细胞具有有效的抗增殖活性。GRO26B已经进入I期临床试验。它们对多种类型的肿瘤(包括肺癌、前列腺癌、乳腺癌和结肠癌)都有活性,对恶性细胞有很高的选择性。这些适体的分子靶标已被确定为核蛋白,这是一种在癌细胞核仁和质膜中高度表达的多功能磷酸化蛋白。在许多肿瘤类型中,高水平的核仁蛋白表达预示着肿瘤的快速生长和不良预后。核仁蛋白在肿瘤细胞的表面而不是在正常细胞的表面我们已经证明分子选择性地靶向它进入肿瘤细胞比正常细胞更优先。因此,核蛋白是一种癌症选择性靶点,其靶向分子不进入正常细胞,潜在的副作用和毒性较低。我们正在采取跨学科的方法来发现新的靶向核蛋白的小分子。初步数据表明,靶向核蛋白的分子(例如,GRO26B和我们已经使用我们的方法确定的小分子)也可以对癌细胞表现出生长抑制活性,而不影响正常细胞。我们建议,在了解GROs和小分子如何与核蛋白结合时,我们可以使用基于结构的药物设计来产生新的小分子,这些小分子比基于寡核苷酸的治疗具有更高的疗效。具体来说,我们需要了解GROs的性质和结构以及它们之间的关系。利用这些信息,我们可以检查与核仁蛋白的配合物,以确定有利的特定相互作用。我们将以这些区域为目标,筛选新的化合物,随后进行抗癌效果测试。本研究的意义在于可以建立一类新的以核蛋白为靶点的低毒性小分子抗癌药物。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John O Trent其他文献

John O Trent的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John O Trent', 18)}}的其他基金

COBRE: LOUISVILLE RES FOUND INC: CORE C: MOLECULAR MODELING FACILITY
COBRE:LOUISVILLE RES FOUND INC:Core C:分子建模设施
  • 批准号:
    8360665
  • 财政年份:
    2011
  • 资助金额:
    $ 24.77万
  • 项目类别:
COBRE: LOUISVILLE RES FOUND INC: CORE C: MOLECULAR MODELING FACILITY
COBRE:LOUISVILLE RES FOUND INC:Core C:分子建模设施
  • 批准号:
    8167777
  • 财政年份:
    2010
  • 资助金额:
    $ 24.77万
  • 项目类别:
COBRE: LOUISVILLE RES FOUND INC: CORE C: MOLECULAR MODELING FACILITY
COBRE:LOUISVILLE RES FOUND INC:Core C:分子建模设施
  • 批准号:
    7959805
  • 财政年份:
    2009
  • 资助金额:
    $ 24.77万
  • 项目类别:
COBRE: LOUISVILLE RES FOUND INC: CORE C: MOLECULAR MODELING FACILITY
COBRE:LOUISVILLE RES FOUND INC:Core C:分子建模设施
  • 批准号:
    7720764
  • 财政年份:
    2008
  • 资助金额:
    $ 24.77万
  • 项目类别:
COBRE: LOUISVILLE RES FOUND INC: CORE C: MOLECULAR MODELING FACILITY
COBRE:LOUISVILLE RES FOUND INC:Core C:分子建模设施
  • 批准号:
    7610536
  • 财政年份:
    2007
  • 资助金额:
    $ 24.77万
  • 项目类别:
COBRE: LOUISVILLE RES FOUND INC: CORE C: MOLECULAR MODELING FACILITY
COBRE:LOUISVILLE RES FOUND INC:Core C:分子建模设施
  • 批准号:
    7382008
  • 财政年份:
    2006
  • 资助金额:
    $ 24.77万
  • 项目类别:
Development of Nucleolin targeted Anticancer Compounds
核素靶向抗癌化合物的开发
  • 批准号:
    6907002
  • 财政年份:
    2005
  • 资助金额:
    $ 24.77万
  • 项目类别:
Development of Nucleolin targeted Anticancer Compounds
核素靶向抗癌化合物的开发
  • 批准号:
    7216224
  • 财政年份:
    2005
  • 资助金额:
    $ 24.77万
  • 项目类别:
Development of Nucleolin targeted Anticancer Compounds
核素靶向抗癌化合物的开发
  • 批准号:
    7031570
  • 财政年份:
    2005
  • 资助金额:
    $ 24.77万
  • 项目类别:
Development of Nucleolin targeted Anticancer Compounds
核素靶向抗癌化合物的开发
  • 批准号:
    7568919
  • 财政年份:
    2005
  • 资助金额:
    $ 24.77万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 24.77万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 24.77万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 24.77万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 24.77万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 24.77万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 24.77万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 24.77万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 24.77万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 24.77万
  • 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
  • 批准号:
    2706416
  • 财政年份:
    2022
  • 资助金额:
    $ 24.77万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了